Use of antidepressants among Canadian workers receiving depression-related short-term disability benefits

Psychiatric Services

Volumn 54, Issue 5, 2003, Pages 724-729

  Dewa, Carolyn S ^a,b   Hoch, Jeffrey S ^c   Goering, Paula ^a,b   Lin, Elizabeth ^a,b,d   Paterson, Michael ^d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CANADA; COST BENEFIT ANALYSIS; DEPRESSION; DISABILITY; DISEASE SEVERITY; DRUG COST; EMPLOYEE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL HEALTH; PRACTICE GUIDELINE; PRESCRIPTION; TREATMENT OUTCOME; WORKMAN COMPENSATION;

ADULT; ANTIDEPRESSIVE AGENTS; CANADA; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER; DISABLED PERSONS; EMPLOYMENT; FEMALE; HUMANS; INSURANCE BENEFITS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0037865542     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.5.724     Document Type: Article

References (33)

1. Kessler RC, Barber C, Birnbaum HG, et al: Depression in the workplace: effects on short-term disability. Health Affairs 18(5):163-171, 1999
2. Berndt E, Bailit HL, Keller MB, et al: Health care use and at-work productivity among employees with mental disorders. Health Affairs 19(4):244-256, 2000
3. Birnbaum HG, Greenberg PE, Barton M, et al: Workplace burden of depression: a case study in social functioning using employer claims data. Drug Benefit Trends 11(8):6BH-12BH, 1999
4. Greenberg PE, Stiglin LE. Finkelstein SN, et al: The economic burden of depression in 1990. Journal of Clinical Psychiatry 54: 405-418, 1993
5. Berndt ER, Finkelstein SN, Creenberg PE, et al: Workplace performance effects from chronic depression and its treatment. Journal of Health Economics 17:511-530, 1998
6. Claxton AJ, Chawla AJ, Kennedy S: Absenteeism among employees treated for depression. Journal of Occupational and Environmental Medicine 41:605-611, 1999
7. Mintz J, Mintz LI, Arruda MJ, et al: Treatments of depression and the functional capacity to work. Archives of General Psychiatry 49:761-768, 1992
8. Prescription Drug Expenditures in 2000: The Upward Trend Continues. Washington, DC, National Institutes for Health Care Management, 2000
9. Foote SM, Etheredge L: Increasing use of new prescription drugs: a case study Health Affairs 19(4):165-170, 2000
10. Dewa CS, Goering P: Lessons learned from trends in psychotropic drug expenditures in a Canadian province. Psychiatric Services 52:1245-1247, 2001
11. Kleinke JD: Just what the HMO ordered: the paradox of increasing drug costs. Health Affairs 19(2):78-91, 2000
12. Chernew M, Cowen ME, Kirking DM, et al: Pharmaceutical cost growth under capitation: a case study. Health Affairs 19(6): 266-276, 2000
13. Barents Group LLC: Factors Affecting the Growth of Prescription Drug Expenditures. Washington, DC, National Institutes for Health Care Management, 1999
14. Olfson M, Marcus SC, Druss B, et al: National trends in the outpatient treatment of depression. JAMA 287:203-209, 2002
15. Statistics Canada: Labour Force 15 Years and Over by Broad Occupational Categories and Major Groups (Based on the 1991 Standard Occupational Classification) and Sex, for Canada, Provinces and Territories, 1991 and 1996 Censuses (20% Sample Data). Catalogue 93F0027XDB96007 in the Nation Series, Ottawa, 1996
16. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
17. Dewa CS, Goering P, Lin E, et al: Depression-related short-term disability in an employed population. Journal of Occupational and Environmental Health 44:628-633, 2002
18. Spigset O, Mårtensson B: Drug treatment of depression. British Medical Journal 318:1188-1191, 1999
19. Thompson D, Buesching D, Gregor KJ, et al: Patterns of antidepressant use and their relation to costs of care. American Journal of Managed Care 2:1239-1246, 1996
20. Melfi CA, Chawla AJ, Croghan TW, et al: The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry 55:1128-1132, 1998
21. American Psychiatric Association Practice Guideline for Major Depressive Disorder in Adults. American Journal of Psychiatry 150(4 supple):iii-26, 1993
22. Depression in Primary Care: Volume 2: Treatment of Major Depression. Pub 93-0551. Washington, DC, Agency for Health Care Policy and Research, 1993
23. Canadian Network for Mood and Anxiety Treatment: Guidelines for the Diagnosis and Pharmacological Treatment of Depression. Toronto, Centre for Addiction and Mental Health, 1999
24. Simon CE, VonKorff M, Wagner EH, et al: Patterns of antidepressant use in community practice. General Hospital Psychiatry 15: 399-408, 1993
25. Offord DR, Boyle MH, Campbell D, et al: One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Canadian Journal of Psychiatry 41:559-563, 1996
26. Katz SJ, Kessler RC, Lin E, et al: Medication Management of Depression in the United States and Ontario. Journal of General Internal Medicine 13:77-85, 1998
27. Sclar DA, Skaer TL, Robinson LM, et al: Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions. Depression and Anxiety 8(suppl 1):121-127, 1998
28. Tierney R, Melfi CA, Signa W, et al: Antidepressant use and use patterns in naturalistic settings. Drug Benefit Trends 12: 7-12, 2000
29. Dewa CS, Hoch JS, Goering P: Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures. Clinical Therapeutics 23:292-306, 2001
30. Melfi CA, Croghan TW: Use of claims data for research on treatment and outcomes of depression care. Medical Care 37:AS77-AS80, 1999
31. Browne RA, Melfi CA, Croghan TW, et al: Issues to consider when conducting research using physician-reported antidepressant claims. Drug Benefit Trends 10: 33;37-42, 1998
32. Motheral BR, Fairman KA: The use of claims databases for outcomes research: rationale, challenges, and strategies. Clinical Therapeutics 19:346-366, 1997
33. Edgell ET, Summers KH, Hylan TR, et al: A framework for drug utilization evaluation in depression insights from outcomes research. Medical Care 37:AS67-AS76, 1999